Emcure Ahmedabad Unit Under USFDA Scanner, Gets 7 Procedural Observations
New Delhi: Emcure Pharmaceuticals has informed the stock exchanges that the United States Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at its formulations manufacturing facility located at GIDC, Taluka-Sanand, Ahmedabad, Gujarat.
According to the company’s regulatory filing, the inspection was carried out from May 6, 2026 to May 15, 2026 at the formulations facility situated in Sanand, Ahmedabad.
At the conclusion of the inspection, the USFDA issued a Form 483 containing seven observations. The company clarified that all the observations issued by the US health regulator are procedural in nature.
A Form 483 is issued by the USFDA when investigators identify conditions that may indicate possible deviations from regulatory or manufacturing compliance requirements during an inspection.
Emcure Pharmaceuticals stated that it is comprehensively addressing the observations raised by the USFDA and will submit its response to the regulator within the stipulated timeframe.
The company disclosed the development through a regulatory filing submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Emcure further requested the stock exchanges to take the information on record.
